Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Generating monoclonal antibodies that selectively and specifically recognize epitranscriptomic modifications.

Project description

Novel antibody production technology

Antibodies against small molecules are generated using traditional methods that involve conjugation to a large protein carrier and injection into animals together with an adjuvant. However, the resultant monoclonal antibodies often exhibit low specificity, selectivity and sensitivity. The EU-funded EPIMODKIT project is working on a novel immunisation platform that produces highly specific antibodies. Using this approach, scientists will focus on antibodies against epitranscriptomic modifications encountered in cellular mRNAs, such as N6-Methyladenosine (m6A) modifications. The EPIMODKIT antibodies will help delineate the role of these mRNA modifications in health and disease.

Objective

Epitranscriptomic modifications constitute specific marks in mRNA that regulate gene expression. Identification of
epitranscriptomic modifications requires next generation sequencing analyses and specific validation, processes that are cumbersome and time consuming. Furthermore, while some modifications are straightforward to identify, as they cause specific base changes (like RNA
editing), most are only detectable either through chemical means (requiring large quantities of material) or by immunoprecipitation
followed by sequencing. Of these techniques, immunoprecipitation requires far less material and can be used in any molecular
biology laboratory, but depends exquisitely on the quality of the monoclonal antibodies that recognize the modification - their
specificity, selectivity and sensitivity.
Most anti-modification antibodies are generated using traditional methods for the production of monoclonals to small
molecule haptens (e.g. conjugation to a large protein carrier and injection into animals together with an adjuvant). While these
methods can generate anti-hapten responses with some specificity they are generally not very selective. We have developed a novel
immunization platform that exquisitely focuses the antibody response to a hapten to generate high affinity monoclonals with a high
degree of specificity. We propose to employ this approach to generate anti-inosine antibodies (for the detection of editing in disease
contexts); anti-m6A antibodies (which would be benchmarked against the ones currently in use, validating our approach); and
antipseudo-uridine antibodies (a tool that is lacking in the field and for which traditional approaches have completely failed). The generation of specific and selective antibodies to these three modifications, will open the way toward a better understanding of their intricate molecular roles in biological proceGenerating monoclonal antibodies that selectively and specifically recognize epitranscriptomic modifications.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 100 000,00
Address
IM NEUENHEIMER FELD 280
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (2)